Giuseppina Brancaccio
A5107305061- Hepatitis C virus research
- Liver Disease Diagnosis and Treatment
- Hepatitis B Virus Studies
- Liver Disease and Transplantation
- HIV/AIDS drug development and treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Systemic Lupus Erythematosus Research
- Hepatitis Viruses Studies and Epidemiology
- SARS-CoV-2 detection and testing
- Amoebic Infections and Treatments
- Gut microbiota and health
- SARS-CoV-2 and COVID-19 Research
- Drug-Induced Hepatotoxicity and Protection
- Advanced biosensing and bioanalysis techniques
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Biochemical and Molecular Research
- Organ Transplantation Techniques and Outcomes
- Vaccine Coverage and Hesitancy
- Dermatological diseases and infestations
- Respiratory viral infections research
- Forensic Entomology and Diptera Studies
- COVID-19 diagnosis using AI
- COVID-19 and healthcare impacts
- Influenza Virus Research Studies
- Cytomegalovirus and herpesvirus research
University of Padua
2018-2024
University of Campania "Luigi Vanvitelli"
2006-2021
Federico II University Hospital
2020
University of Naples Federico II
2010-2019
Italian Medicines Agency
2018
Bristol-Myers Squibb (Germany)
2018
Johnson & Johnson (Israel)
2018
Janssen (Switzerland)
2018
Gilead Sciences (Australia)
2018
Azienda Ospedaliero-Universitaria di Modena
2017
Therapy of chronic hepatitis delta with standard interferon therapy has met limited efficacy. This study was designed to examine the efficacy and safety peginterferon or without ribavirin. Thirty-eight serum B surface antigen- HDV RNA-positive patients alanine aminotransferase (ALT) more than 1.5 times upper normal limit received alpha-2b (1.5 μg/kg) alone as monotherapy (n = 16) in combination ribavirin 22), for 48 weeks. Thereafter, all were maintained on 24 weeks followed off therapy. The...
Few data are available on the virological and clinical outcomes of advanced liver disease patients retreated after first-line DAA failure.
Abstract Background & Aims Despite the excellent efficacy of direct‐acting antivirals ( DAA ) reported in clinical trials, virological failures can occur, often associated with development resistance‐associated substitutions RAS s). This study aimed to characterize presence clinically relevant s all classes real‐life failures. Methods Of 200 that were analyzed 197 ‐treated patients, 89 pegylated‐interferon+ribavirin (Peg IFN + RBV and 111 without HCV ‐1a/1b/1g/2/3/4=58/83/1/6/24/25;...
Summary Background Suppression of hepatitis B virus (HBV) replication with nucelos(t)ide analogues should be considered for patients chronic D (HDV) infection and ongoing HBV replication. Aim To verify the clinical outcome after long‐term entecavir or tenofovir treatment in advanced fibrosis/cirrhosis, ineligible to peg‐interferon therapy. Methods Patients were prospectively followed‐up at 3‐6 month intervals; measured outcomes decompensation, hepatocellular carcinoma (HCC), liver transplant...
Background There are few real-life data on the potential drug-drug interactions (DDIs) between anti-HCV direct-acting antivirals (DAAs) and comedications used. Aim To assess DDIs of DAAs in HCV-infected outpatients, according to severity liver disease comedication used a prospective multicentric study. Methods Data from patients 15 clinical centers who had started DAA regimen were receiving during March 2015 2016 prospectively evaluated. The for each assigned HepC Drug Interactions...
Abstract Natural resistance-associated substitutions (RASs) are reported with highly variable prevalence across different HCV genotypes (GTs). Frequency of natural RASs in a large Italian real-life cohort patients infected the 4 main HCV-GTs was investigated. NS3, NS5A and NS5B sequences were analysed 1445 HCV-infected DAA-naïve patients. Sanger-sequencing performed by home-made protocols on 464 GT1a, 585 GT1b, 92 GT2c, 199 GT3a, 16 GT4a 99 GT4d samples. Overall, 20.7% (301/1455) showed...
Background and aimsSevere liver disease markers assessed before HCV eradication are acknowledged to usually improve after the SVR. We prospectively evaluated, in PITER cohort, long-term HCC risk profile based on predictors monitored by direct-acting antivirals patients with cirrhosis.MethodsHCC occurrence was evaluated Kaplan-Meier analysis. Cox regression analysis identified post-treatment variables associated de-novo HCC; their predictive power presented a nomogram.ResultsAfter end of...
The study measures trends in the profile of patients with chronic hepatitis B virus linked to care Italy.A cross-sectional, multicenter, observational cohort (PITER cohort) consecutive surface antigen (HBsAg) over period 2019-2021 from 46 centers was evaluated. reference MASTER collected years 2012-2015. Standard statistical methods were used.The PITER enrolled 4583 patients, whom 21.8% non-Italian natives. Compared those MASTER, older and more often female. prevalence e (HBeAg) declined...
The treatment of hepatitis C virus (HCV) with direct-acting antivirals (DAA) leads to high sustained virological response (SVR) rates, but hepatocellular carcinoma (HCC) risk persists in people advanced liver disease even after SVR. We weighted the HCC cirrhosis achieving HCV eradication through DAA and compared it untreated participants multicenter prospective Italian Platform for Study Viral Hepatitis Therapies (PITER) cohort. Propensity matching inverse probability weighting was used...
BackgroundInternational consensus has recently introduced a new definition of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). We sought to analyse epidemiological trends, prognostic features, and transplant survival benefits MASLD non-MASLD patients waiting for liver transplantation (LT) in Italy.Materials methodsUtilising the Italian Transplant Registry database, we analysed data from adult listed primary LT due end-stage chronic disease between January 2012 December 2022....
Advances in direct-acting antiviral treatment of HCV have reinvigorated public health initiatives aimed at identifying affected individuals. We evaluated the possible impact only diagnosed and linked-to-care individuals on overall burden estimates identified a strategy to achieve WHO targets by 2030.Using modelling approach grounded Italian real-life data treated patients, different linkage-to-care scenarios were built evaluate potential strategies achieving elimination goals.Under 40%...
It is paramount to identify predictors of treatment failure with direct antiviral agents in 'field-practice' patients, including people who inject drugs (PWID). Data on the efficacy glecaprevir/pibrentasvir (GLE/PIB) a field-practice scenario are scant. The multicentre MISTRAL study enrolled 1177 PWID, assess real-life and safety GLE/PIB predictive factors for this treatment.This was prospective, longitudinal study. outcome variable rate sustained virological response (SVR) at week 12.A...
ABSTRACT SARS-CoV-2 genetic variants are emerging as a major threat to vaccination efforts worldwide they may increase virus transmission rate and/or confer the ability escape vaccine induced immunity with knock on effects level of herd and efficacy respectively. These concern Spike protein, which is encoded by S gene, involved in entry into host cells target development. We report here that N gene can impair our utilize antigenic tests for both diagnosis mass testing aimed at controlling...
Mixed cryoglobulinemia is the most common HCV extrahepatic manifestation. We aimed to prospectively evaluate cryoglobulinemic vasculitis (CV) clinical profile after a sustained virologic response (SVR) over medium-term long-term period.
Abstract Population testing remains central to COVID-19 control and surveillance, with countries increasingly using antigen tests rather than molecular tests. Here we describe a SARS-CoV-2 variant that escapes N due multiple disruptive amino-acid substitutions in the protein. By fitting multistrain compartmental model genomic epidemiological data, show widespread Italian region of Veneto favored undetected spread antigen-escape compared rest Italy. We highlight novel limitations absence for...